ImmunoCellular Therapeutics,(ICT) Ltd has announced that the company acquired the exclusive license from the Cedars-Sinai Medical Center for their novel peptides which the Company believes can stimulate the immune system to target cancer stem cells. Thus it can be used for gliomas, a cancer originating in the brain or spine. These peptides were specifically designed to elicit a T cell response targeting CD133 positive cancer stem cells that have been identified in a number of cancer types, including gliomas, colon cancer and pancreatic cancer.
Read the rest of this entry (255 words) »